Figure 1 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Trial schema for parts 1–3. *Expansion cohort into patients with neuroendocrine tumors (NET). Based on the lack of efficacy in the combination arm, further monotherapy expansion cohorts were abandoned. † Labeled dose/regimen of avelumab. ‡ Combination therapy safety lead in. No attrition was observed.